http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109371021-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2018-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109371021-B |
| titleOfInvention | A method of treating HPV-positive cervical intraepithelial neoplasia using CRISPR/Cas9 |
| abstract | The present invention provides a method for treating HPV-positive cervical intraepithelial neoplasia using CRISPR/Cas9. The present invention adopts the way of plasmid transfection through the vagina, and uses the CRISPR/Cas9 gene editing technology to destroy the target gene E7, reduce the viral load, and restore the function of the tumor suppressor RB, thereby reversing the malignant phenotype of the host cell and greatly reducing the cost of treatment and psychological burden on patients. The role of CRISPR/Cas9 gene editing technology in a mouse animal model of K14‑HPV16 cervical intraepithelial neoplasia makes it a very promising therapeutic modality for the treatment of cervical intraepithelial neoplasia. The gRNA can effectively treat HPV-positive cervical intraepithelial neoplasia, has significant advantages over the gRNA of the prior art, and is suitable for clinical and patient use. |
| priorityDate | 2018-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.